WASHINGTON, Nov. 18, 2026
The White House has withdrawn Dr. Heidi Overton's nomination to lead the Food and Drug Administration. It pulled the pick on Tuesday, Nov. 17, one day before the Senate health committee was scheduled to vote on her. Several outlets reported she did not have enough Republican support to move forward.

The decision leaves the FDA without a Senate-confirmed commissioner for more than six months. For drug, biotech and medical device companies, that uncertainty may matter more than the nomination fight itself.

Why was Heidi Overton's nomination pulled?

The numbers on the Senate Health, Education, Labor and Pensions (HELP) committee were tight. Republicans hold 12 of its 23 seats, so if every Democrat voted no, losing a single Republican would have been enough to block her.

Committee chair Sen. Bill Cassidy (R-La.), a physician, said Tuesday he was still undecided. He had criticized her role in a White House executive order to split up and space out childhood vaccines, including the MMR shot, calling her support for it "almost disqualifying." He had also raised concerns about her lack of management experience. Cassidy lost his primary in June and leaves the Senate in weeks, which gave him little reason to fall in line.

Sen. Susan Collins (R-Maine) questioned Overton over the FDA's recent approval of fruit-flavored e-cigarettes. Democrats focused on her past writing, which called mail delivery of the abortion pill mifepristone dangerous. She also faced pushback from parts of the Make America Healthy Again movement, whose figures accused her of putting industry ahead of Health Secretary Robert F. Kennedy Jr.'s priorities.

Who could replace Overton?

Republicans have discussed Sen. Roger Marshall of Kansas as a possible replacement, Semafor reported, citing four people familiar with the talks. Marshall, a physician who recently lost his re-election bid, is seen by some Republicans as an easier nominee to confirm. The White House has not announced a decision.

Who is running the FDA now?

Kyle Diamantas, a lawyer who previously led the agency's food division, has been acting commissioner since Marty Makary resigned in May.

That may not last. A Trump administration official told Semafor that Diamantas, who never wanted the job permanently, is weighing leaving the FDA. Politico has reported that former acting commissioner Sara Brenner could be asked to return on a temporary basis. Neither move has been officially announced.

Heidi Overton FDA Nomination Withdrawn: What It Means for Pharma

What this means for drug and device companies

The real business question is how long the FDA stays without a confirmed leader. Four things are worth watching:

- Big decisions may stall. Acting leaders usually avoid major policy changes, so open issues like the FDA's safety review of mifepristone and its stance on flavored vapes could stay unresolved.
- Staffing is stretched. The FDA has lost about 20% of its workforce since Trump took office, according to the Associated Press. Thinner review teams can affect meeting schedules and guidance timelines.
- Fast-track programs are uncertain. Reuters reported, citing unnamed sources, that the agency has shelved the Commissioner's National Priority Voucher program, which Makary created to speed up select reviews.
- Confirmation gets harder in 2027. Democrats take control of the Senate in January, so any nominee not confirmed by then will face a tougher chamber.

During her September hearing, Overton's main pitch was speeding up drug development so the US can compete with China. Companies hoping for that kind of push from the top will now have to wait.

The White House has not said when it will name a new nominee, or whether the Senate will try to confirm one during the lame-duck session before Democrats take control in January. If no one is confirmed by then, the commissioner's job could stay open well into the new year.

Lobox will update this story when a new nominee is announced.